Drug Delivery Business News’ Post

There is already a significant trend in the usage of wearable injectors (OBDS) 𝐁𝐔𝐓: However, with the decision for a portable device, new CHALLENGES of varying complexity become apparent. Keywords are:      - High measuring accuracy of the injection depth - Evaporation of drug during injection process (up to 60 min) - Avoiding static charges during the injection process - Crystallization of biologicals on contact with air - Determination of the complete injection volume for highly viscous drugs (incl. last drop) - Compatibility with FDA 21 CFR Part 11 𝐙𝐰𝐢𝐜𝐤𝐑𝐨𝐞𝐥𝐥‘𝐬 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 𝐚𝐮𝐭𝐨-𝐢𝐧𝐣𝐞𝐜𝐭𝐨𝐫𝐬 𝐠𝐮𝐚𝐫𝐚𝐧𝐭𝐞𝐞 𝐫𝐞𝐥𝐢𝐚𝐛𝐥𝐞 𝐭𝐞𝐬𝐭 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐚𝐥𝐬𝐨 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐩𝐨𝐫𝐭𝐚𝐛𝐥𝐞 𝐬𝐲𝐬𝐭𝐞𝐦𝐬, 𝐚𝐬 𝐭𝐡𝐞 𝐬𝐞𝐧𝐬𝐨𝐫 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐞𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧 𝐦𝐞𝐭𝐡𝐨𝐝𝐬 𝐮𝐬𝐞𝐝 𝐜𝐚𝐧 𝐛𝐞 𝐭𝐫𝐚𝐧𝐬𝐟𝐞𝐫𝐫𝐞𝐝 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐚𝐥𝐫𝐞𝐚𝐝𝐲 𝐩𝐫𝐨𝐯𝐞𝐧 𝐬𝐲𝐬𝐭𝐞𝐦𝐬 Our esteemed colleague James Ritchey reports on this in the Quality Magazine – it is worth to read it! https://lnkd.in/ejGqsGQY #ISO11608 #MedicalTesting

Microneedle sensors could enable minimally-invasive, continuous molecular monitoring – informing on disease status and treatment in real-time. Wearable sensors for pharmaceuticals, for example, would create opportunities for treatments personalized to individual pharmacokinetics. Here, we demonstrate a commercial-off-the-shelf (COTS) approach for microneedle sensing using an electrochemical aptamer-based sensor that detects the high-toxicity antibiotic, vancomycin. Wearable monitoring of vancomycin could improve patient care by allowing targeted drug dosing within its narrow clinical window of safety and efficacy. To produce sensors, we miniaturize the electrochemical aptamer-based sensors to a microelectrode format, and embed them within stainless steel microneedles (sourced from commercial insulin pen needles).

Automating your medical device assembly offers numerous advantages including heightened quality, consistency, improved throughput, and decreased cost. The ongoing rise in demand for medical, pharmaceutical, diagnostic, and surgical devices underlines the importance of implementing automation into your device assembly process. Whether you require automated solutions for medication delivery devices, fluid sets, diagnostic products and kits, surgical devices, implantable devices, diabetes management products, wearables, etc., our team of experts is ready to collaborate with you to create a tailored solution that perfectly matches your unique needs. Learn more about our Life Science Division here: https://lnkd.in/gGhsBZRa #medicalautomation #medicaldevice #assembly #automation

Shipping and storing advanced therapeutics can be complex and costly if not done efficiently. But, there's good news! With advancements in drug accountability, wearable devices, and emerging technology such as automation and machine learning, supply chain efficiency can be increased. In an article by IQVIA Technologies, learn how this is able to capture real-time factors important for patient safety and protocol adherence, reducing the risk of wasted IP: https://lnkd.in/etvvsNG8 #SupplyChainEfficiency #PatientSafety #EmergingTechnology

Exciting times ahead for pharmaceutical marketing! Read on and discover how VR, AR, wearable tech, and AI are reshaping engagement strategies in the pharmaceutical industry ➡️https://lnkd.in/efKu7vD7 #circus #doitvirtually #pharma #marketing #virtualreality #virtualtech #ar #ai

Lilly revolutionizes clinical trials with intelligent sensor cloud The pharmaceutical giant has developed a cloud solution with MagnolAI for continuously ingesting, visualizing, and transforming digital biomarker data into meaningful medical insights. Digital biomarkers are increasingly playing an important role in improving our understanding of disease and health. Defined as quantifiable and objective behavioral and physiological data collected and measured by digital devices such as implantables, wearables, ingestibles, or portables, digital biomarkers enable pharmaceutical companies to conduct studies remotely without the need for a physical site. This innovative approach is revolutionizing the way pharmaceutical firms conduct research and determine treatment effectiveness. - https://lnkd.in/g_vpVEuB

According to our research the global market for medical devices is estimated at US$ 603 billion in the year 2023 and will be growing at a CAGR of 5% during next six years. #MedicalMarijuanaPackaging #GlobalMarket #FlowerPackaging #ConcentratePackaging #EdiblePackaging #OnlineMarket #Dispensaries #MarketGrowth #MarketOutlook #MedicalDevices

𝐓𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐦𝐚𝐫𝐭 𝐏𝐢𝐥𝐥𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 𝟏.𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟐𝟖 𝐟𝐫𝐨𝐦 𝐔𝐒𝐃 𝟎.𝟔 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑, 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟏𝟏.𝟖% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝. 🔥 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 + 𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐓𝐎𝐂 ➡️ https://lnkd.in/duK6NvMV rowth in this market is majorly driven by the rise in demand for non-invasive diagnostic monitoring devices, technological advancements in capsule endoscopy and significant advancements in capsule endoscopy technology. The growing demand for advanced drug delivery systems and need for a rapid drug development process are expected to offer opportunities for market players during the forecast period. On the other hand, technological incompetence of smart pills in some conditions is expected to restrain the market growth to some extent in the coming years 🌟 𝐓𝐨𝐩 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:  ✅ RF Medical Co., Ltd. (Japan) ✅ etectRx (US) ✅ Olympus Corporation (Japan) ✅ BodyCAP (France) ✅ Chongqing Jinshan Science & Technology (group) Co., Ltd. (China) ✅ Check-Cap Ltd. (Israel) ✅ CapsoVision, Inc. (US) ✅ AnX Robotica Corp. (US) ✅ Medtronic plc (US) ✅ IntroMedic Co.,Ltd (South Korea) ✅ @Shenzen Jifu Medical Technology Co., Ltd (China) ✅ OTSUKA AMERICA PHARMACEUTICAL INC Pharmaceutical, Inc. (US)

Pharmapack Paris January 2024. At Europe's leading Drug Delivery and packaging event 22 January 2024, Paris, over 5,000 attendees representing 363 companies from 70 countries showcased their products and services. 50 different content sessions and panel discussions over the two days enabled insightful and informative discussions with thought-provoking Q&A's. Talks focused on opportunities and challenges in connected drug delivery, next-gen wearable devices, precision drug delivery and ecosystem considerations in adopting large volume on-body injectors all highlighted the significant challenges MedTech and Biopharmaceutical companies face when bringing a new Combination Product & Drug Delivery device to market. Emerging themes spanned personalised drug delivery systems, the rise of digital health technologies including software as medical devices, telemedicine and wearables through to futuristic topics such as digitally connected therapeutics, real-time monitoring and the creation of interactive feedback loops (with the associated regulatory, privacy, ethical and cybersecurity challenges surrounding the careful safeguarding of patient data). With many commentators confirming healthcare is at the very beginning of a twin, bio and digital revolution, the need to accelerate, broaden and deepen collaboration is perhaps greater now than ever before.... Ed Birmingham Soroosh Bagheriasl , PhD Scott Ewan Victoria Ludlow Alaster Stockwell-Jones #collaboration #connection #progress #medtech #innovation #biopharmaceutical  

🌟 Exciting Global Health Innovation Alert! 🌍📱 Yale University and Mayo Clinic partner with Biofourmis to revolutionize heart failure drug development using wearable biometric data! 💊⌚️ In a 60-day study starting this August, researchers will analyze patient-centric endpoints through #Biofourmis' mobile health platform, #BiovitalsHF, with the help of Apple Watch and Everion biosensors. 📊🏥 This collaboration, aligning with FDA guidance, aims to streamline clinical trials, accelerate drug approval, and personalize therapies for better patient outcomes. 💪🔬 #HealthTech #PrecisionMedicine #ClinicalResearch 🚀